12.1 Site Startup Operations

Overview of Site Startup

Site startup is one of the most resource-intensive and critical phases in the lifecycle of a clinical trial. It spans from the initial contact by a sponsor or Contract Research Organization (CRO) to the point where the site is fully activated and ready to screen its first subject. For a Clinical Research Coordinator (CRC), mastering startup operations is essential, as delays in this phase directly impact the overall timeline of the trial.

The startup phase typically involves several parallel tracks: site feasibility and selection, regulatory document collection, Institutional Review Board (IRB) or Independent Ethics Committee (IEC) submissions, and contract/budget negotiations.

Site Feasibility and Qualification

Before a site is selected, the sponsor must determine if the site has the appropriate patient population, facilities, and experienced staff to conduct the trial. This process begins with a Site Feasibility Questionnaire.

The Feasibility Questionnaire

The CRC often takes the lead in completing the feasibility questionnaire in collaboration with the Principal Investigator (PI). This document requests detailed information regarding:

• Patient Population: Retrospective data on how many patients with the target indication the site sees per month, and a realistic estimate of how many could be enrolled.
• Competing Trials: Whether the site is currently conducting other trials that target the same patient population, which could hinder enrollment.
• Site Infrastructure: Availability of required equipment (e.g., -70°C freezers, centrifuges, specific imaging modalities like MRI or PET scanners).
• Staffing: The experience level of the PI, sub-investigators, CRCs, and other key personnel.

Pre-Study Visit (PSV) / Site Selection Visit (SSV)

If the feasibility questionnaire indicates that the site is a good fit, the sponsor or CRO will schedule a Pre-Study Visit (PSV), also known as a Site Selection Visit (SSV). During this visit, a Clinical Research Associate (CRA) will:

1. Tour the facility to verify the infrastructure.
2. Meet with the PI to discuss the protocol and gauge their interest and commitment.
3. Review the proposed recruitment strategy.
4. Assess the experience and availability of the research staff.

Pro-Tip for CRCs: Prepare for the PSV by reserving a quiet space for the CRA, ensuring the PI is available for their scheduled time, and having requested documentation (like equipment calibration logs) readily available.

Essential Regulatory Documents

Once a site is selected, the regulatory startup phase begins. The CRC or a dedicated Regulatory Coordinator must compile the essential document packet. These documents are required by Good Clinical Practice (GCP) and regulatory agencies (like the FDA) before investigational product (IP) can be shipped to the site.

Key Regulatory Documents

Gathering these documents promptly is a primary responsibility. A common bottleneck is obtaining signatures from busy physicians, so setting up an efficient e-signature workflow or dedicated signing times can expedite the process.

IRB/IEC Submissions

No clinical trial procedures can begin until the study has been reviewed and approved by an Institutional Review Board (IRB) or Independent Ethics Committee (IEC). The IRB's primary mandate is to protect the rights, safety, and well-being of human subjects.

Central vs. Local IRBs

Sites may use a Local IRB (typically an internal committee at a university or large hospital system) or a Central IRB (an independent, commercial board used by multiple sites in a multicenter trial).

• Central IRBs: Often process submissions faster. The sponsor usually submits the main protocol and investigator's brochure, while the site submits site-specific details (like the PI's qualifications and site-specific informed consent language).
• Local IRBs: May require more extensive internal routing and approvals (e.g., scientific review committees, radiation safety committees) before the IRB will even review the submission.

The Initial Submission Packet

The CRC typically prepares the initial IRB submission, which must include:

1. The Clinical Trial Protocol (and any amendments).
2. The Investigator's Brochure (IB) (which contains all pre-clinical and clinical data on the investigational product).
3. The Informed Consent Form (ICF). The sponsor provides a master ICF, but the site must add local language regarding subject injury, compensation, and local contact information.
4. Subject-Facing Materials: Any recruitment flyers, radio scripts, questionnaires, or diaries the subject will see.
5. PI Qualifications: The PI's CV and medical license.

Managing IRB Stipulations

Rarely does an IRB approve a study on the first pass without any questions. They will often issue stipulations or requests for modifications. The CRC must review these promptly with the PI, make the necessary changes to the ICF or other documents, and submit the responses. Time is of the essence; a delay in responding to the IRB directly delays site activation.

The Road to Site Activation

Site activation, or the "green light," is the culmination of all startup activities. It means the site has full IRB approval, a fully executed clinical trial agreement (CTA) and budget, and all essential regulatory documents have been approved by the sponsor. Only after receiving this formal notification can the site schedule the Site Initiation Visit (SIV) and eventually begin screening subjects. By managing startup operations proactively, the CRC ensures the site contributes to the trial's success from day one.